AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. RBC Capital Launches AbbVie (ABBV) Coverage, Expects Shares to Outperform Amid Competitive Fears On February 25, RBC Capital analyst Trung Huynh initiated coverage of AbbVie Inc. (NYSE:ABBV) with an Outperform rating and a $260 price target. The analyst noted that the shares have lagged due to concerns that AbbVie’s “beat-and-raise” story may be fading and that rising competition could slow its ...

Core Viewpoint - The Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the efficacy of their drug setrusumab for treating Osteogenesis Imperfecta [1][3]. Group 1: Class Action Details - The class action lawsuit is titled Bailey v. Ultragenyx Pharmaceutical Inc., and it includes purchasers of Ultragenyx common stock from August 3, 2023, to December 26, 2025 [1]. - Investors have until April 6, 2026, to seek appointment as lead plaintiff in the lawsuit [1][6]. - The lawsuit alleges that Ultragenyx misrepresented the reliability of data from its Phase III Orbit study, which failed to show a statistically significant reduction in annualized fracture rate [3]. Group 2: Allegations and Stock Impact - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance, leading to a stock price drop of over 25% [4]. - Following a December 29, 2025 announcement that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock fell more than 42% [5]. - The company attributed the study failures to a low fracture rate in the placebo group and a trend that did not reach statistical significance [5]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Ultragenyx stock during the class period to seek lead plaintiff status [6]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [7].

Group 1 - Palvella Therapeutics, Inc. announced the pricing of its upsized public offering of 1,600,000 shares at $125.00 per share, with expected gross proceeds of $200 million [1] - The offering includes a 30-day option for underwriters to purchase an additional 240,000 shares [1] - The offering is expected to close on or about February 27, 2026, subject to customary closing conditions [1] Group 2 - The net proceeds from the offering will be used to support the development of programs including QTORIN rapamycin and QTORIN pitavastatin, as well as for working capital and general corporate purposes [3] - The offering is made pursuant to a shelf registration statement declared effective by the SEC on January 29, 2026 [4] Group 3 - Palvella is focused on developing therapies for serious, rare skin diseases and vascular malformations, with a pipeline based on its patented QTORIN™ platform [6] - The lead product candidate, QTORIN™ rapamycin, is being developed for microcystic lymphatic malformations and other conditions, while QTORIN™ pitavastatin is for the treatment of disseminated superficial actinic porokeratosis [6][7]

In this article, we will take a look at the 14 Best Affordable Dividend Stocks to Buy According to Analysts.According to a report from Franklin Templeton, dividends have played a much larger role in investor returns than many people realize. From 1960 through the end of last year, about 85% of the S&P 500 Index’s total cumulative return came from reinvested dividends and the effects of compounding.This highlights why dividend-focused strategies remain important. They can offer more stability, a steady incom ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Mereo BioPharma To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Mereo between June 5, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Fa ...

Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% FIRDAPSE® (amifampridine) Growth and 67.5% Growth of AGAMREE® (vamorolone), Reflecting Continued Adoption Full Year 2026 Total Revenues Expected to be Between $615 Million and $645 Million, Reflecting Confidence in Strength and Durability of FIRDAPSE and AGAMREE Franchises Promoted Product Revenue, Net Expected ...

CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the TD Cowen 46th Annual Health Care Conference being held in Boston, MA at the Boston Marriott Copley Place on March 2nd – 4th, 2026. Dr. Aiyar’s presentation will take place on Tuesday, March ...

FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income(1) of $161 Million, Representing 35% Year-Over-Year Growth FY 2025 Adjusted EBITDA(2) of $231 Million, Representing 40% Year-Over-Year Growth Incoming CFO Appointment Expected to Further Enhance Financial Strategy, Working Capital Execution and Capital Allocation Discipline Advancing SG-001 Pipeline Program with Anticip ...

Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference [Accessibility Statement] Skip NavigationBOULDER, Colo., Feb. 25, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m ...

REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets. Fourth Quarter and Full-Year 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the th ...